Phase 3 Invasive Bladder Cancer Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled101 locationsNCT06510374
Recruiting
Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled75 locationsNCT06545955
Recruiting
Phase 3
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center125 enrolled9 locationsNCT06929286
Recruiting
Phase 3
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
Bladder CarcinomaBladder NeoplasmMuscle Invasive Bladder Cancer (MIBC)+2 more
University of Rome Tor Vergata92 enrolled1 locationNCT07067749
Recruiting
Phase 2Phase 3
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Muscular Invasive Bladder Cancer (MIBC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.840 enrolled1 locationNCT06879145
Recruiting
Phase 3
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shaogang Wang180 enrolled3 locationsNCT06696794
Recruiting
Phase 3
Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Non Muscle Invasive Bladder Cancer
Chengdu CoenBiotech Co., Ltd412 enrolled1 locationNCT06241755